Peer-reviewed veterinary case report
MicroRNA differences in dogs with splenic masses versus healthy
By Grimes, Janet A et al.·Published in American journal of veterinary research·2021·Department of Small Animal Medicine and Surgery, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Identification of serum microRNAs with differential expression between dogs with splenic masses and healthy dogs with histologically normal spleens.
- Species:
- dog
Plain-English summary
A group of dogs with splenic masses, including hemangiosarcoma (a type of cancer) and hematomas (blood-filled swellings), were studied to find specific markers in their blood. Researchers discovered five microRNAs (tiny molecules that help regulate genes) that were present in higher amounts in the blood of dogs with these splenic issues compared to healthy dogs. This finding suggests that these microRNAs could potentially be used as a simple blood test to help identify dogs suffering from splenic masses. While this study does not provide treatment outcomes, it highlights a promising area for future diagnostic tools in veterinary medicine.
People also search for: dog splenic mass symptoms · dog hemangiosarcoma blood test · dog hematoma treatment · dog cancer blood markers
Abstract
OBJECTIVE: To identify differential microRNA (miRNA) expression in dogs with splenic hemangiosarcoma, splenic hematoma, and histologically normal spleens. ANIMALS: Dogs with splenic hemangiosarcoma (n = 10), splenic hematoma (n = 5), and histologically normal spleens (n = 5). PROCEDURES: Splenic tissue and serum samples were collected from dogs with splenic masses (ie, hemangiosarcoma or hematoma samples) and healthy control dogs (ie, control samples), and total RNA was extracted. Reverse transcription quantitative real-time PCR was performed with 28 miRNAs associated with hemangiosarcoma, angiosarcoma, or associated genes. Differential expression analysis was performed. RESULTS: Control tissue and serum samples had similar miRNA expression patterns, and hemangiosarcoma tissue and serum samples did not. Hemangiosarcoma serum samples had higher expression than hemangiosarcoma tissue for 13 miRNAs and lower expression for 1 miRNA. Control tissue and hemangiosarcoma tissue had varying expressions for 12 miRNAs, with 10 more highly expressed in control samples and 2 more highly expressed in hemangiosarcoma samples. Five miRNAs (miR-214-3p, miR-452, miR-494-3p, miR-497-5p, miR-543) had significantly different expression in serum between dogs with splenic masses (ie, hemangiosarcoma or hematoma) and serum of dogs with histologically normal spleens, with higher expression in the serum of dogs with splenic masses for all 5 miRNAs. CONCLUSIONS AND CLINICAL RELEVANCE: 5 circulating miRNAs were identified that distinguished dogs with splenic hemangiosarcoma or hematoma from those with histologically normal spleens. These 5 miRNAs had higher expression in dogs with splenic masses, indicating upregulation of these circulating miRNAs occurs in these splenic disease states. These miRNAs may be useful as a noninvasive screening tool that uses serum to identify dogs with splenic masses.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34296940/